Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex
2007

Inhibition of HIV-1 replication by P-TEFb inhibitors

publication Evidence: moderate

Author Information

Author(s): Sebastian Biglione, Sarah A Byers, Jason P Price, Van Trung Nguyen, Olivier Bensaude, David H Price, Wendy Maury

Primary Institution: University of Iowa

Hypothesis

The study investigates whether P-TEFb inhibitors can effectively inhibit HIV-1 replication by releasing free P-TEFb from its large, inactive form.

Conclusion

P-TEFb inhibitors can reduce HIV-1 replication, but their effectiveness is diminished in long-term studies due to increased cytotoxicity.

Supporting Evidence

  • P-TEFb inhibitors were shown to cause a dose-dependent release of free P-TEFb from its large form.
  • Flavopiridol demonstrated the highest therapeutic index among the tested inhibitors.
  • Short-term studies indicated that P-TEFb inhibitors could effectively block HIV-1 replication without significant cytotoxicity.

Takeaway

This study found that certain drugs can help stop HIV from making copies of itself by changing how a protein works in the cell, but they can also be harmful to the cells over time.

Methodology

The study used a combination of in vitro kinase assays, HIV infectivity assays, and differential salt extraction methods to assess the effects of P-TEFb inhibitors on HIV-1 replication.

Limitations

The inhibitors showed increased cytotoxicity and reduced efficacy in long-term studies with primary cells compared to short-term assays.

Digital Object Identifier (DOI)

10.1186/1742-4690-4-47

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication